Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06760182 | Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis | PHASE2 | COMPLETED | 169 | — | — | Mar 10, 2025 | Jul 1, 2025 | Aug 12, 2025 | 30 | China |
Average daily retrospective nasal symptom score (rTNSS) changed from baseline after 2 weeks of treatment. The total score is 0-12 points, with the higher score meaning the more severe symptoms.
| Arm | Type | Description |
|---|---|---|
| TQH2722 injection | EXPERIMENTAL | - |
| TQH2722 Placebo | PLACEBO_COMPARATOR | TQH2722 placebo, 1 weeks as a treatment cycle. |
| Name | Type | Description |
|---|---|---|
| TQH2722 injection | DRUG | TQH2722 injection is a humanized monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα). |
| TQH2722 Placebo | DRUG | Placebo without drug substance. |
Inclusion Criteria: * Aged 18 to 75 years at the screening period. * Patients who met the diagnostic criteria of allergic rhinitis in Chinese Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (revised edition, 2022) * Positive of at least 1 allergen skin prick test(SPT) and/or serum-s...